AN2 Therapeutics, Inc.
NASDAQ:ANTX
1.22 (USD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0.077 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | -0.077 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 40.488 | 54.871 | 29.511 | 16.906 | 6.019 | 4.889 |
| General & Administrative Expenses
| 0 | 14.764 | 12.751 | 4.668 | 1.265 | 1.734 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0.287 |
| SG&A
| 14.066 | 14.764 | 12.751 | 4.668 | 1.265 | 0.289 |
| Other Expenses
| 0 | 0 | -0.045 | -0.038 | -6.322 | 0 |
| Operating Expenses
| 54.554 | 69.635 | 42.262 | 21.574 | 7.284 | 5.178 |
| Operating Income
| -54.554 | -69.635 | -42.262 | -21.574 | -7.284 | -5.178 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.233 | 4.903 | 1.306 | 0.031 | -6.319 | -0.457 |
| Income Before Tax
| -51.321 | -64.732 | -40.956 | -21.543 | -13.603 | -5.635 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0.514 | -0.069 | -0.003 | -0.031 |
| Net Income
| -51.321 | -64.732 | -41.47 | -21.474 | -13.6 | -5.635 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.72 | -2.74 | -2.14 | -1.15 | -0.73 | -0.3 |
| EPS Diluted
| -1.72 | -2.74 | -2.14 | -1.15 | -0.73 | -0.3 |
| EBITDA
| -51.321 | 4.903 | -42.262 | 0 | -6.319 | 0 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |